ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
New Approaches for the Prevention and Treatment of CVD
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 193165" data-attributes="member: 13851"><p><strong>Current and emerging therapies target diverse atherosclerotic processes to reduce the residual risk for atherosclerotic cardiovascular disease events. To address residual risk for cardiovascular events that persist despite guideline-recommended statin therapy, newer agents offer alternative mechanisms to lower low-density lipoprotein cholesterol and advances in our understanding of atherogenesis and atherothrombosis provide emerging approaches to target other lipid and nonlipid parameters such as triglyceride and triglyceride-rich lipoproteins, lipoprotein(a), and inflammation. Abbreviations: ANGPTL3, angiopoietin-like protein 3; APO, apolipoprotein; ASO, antisense oligonucleotide; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HL, hepatic lipase; IDL, intermediate-density lipoprotein; IL, interleukin; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); LPL, lipoprotein lipase; MOA, mechanism of action; PCSK9, proprotein convertase subtilisin/kexin type 9; siRNA, small interfering RNA; TGRL, triglyceride-rich lipoprotein; Treg, regulatory T cell; VLDL, very-low-density lipoprotein</strong></p><p>[ATTACH=full]12324[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 193165, member: 13851"] [B]Current and emerging therapies target diverse atherosclerotic processes to reduce the residual risk for atherosclerotic cardiovascular disease events. To address residual risk for cardiovascular events that persist despite guideline-recommended statin therapy, newer agents offer alternative mechanisms to lower low-density lipoprotein cholesterol and advances in our understanding of atherogenesis and atherothrombosis provide emerging approaches to target other lipid and nonlipid parameters such as triglyceride and triglyceride-rich lipoproteins, lipoprotein(a), and inflammation. Abbreviations: ANGPTL3, angiopoietin-like protein 3; APO, apolipoprotein; ASO, antisense oligonucleotide; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HL, hepatic lipase; IDL, intermediate-density lipoprotein; IL, interleukin; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); LPL, lipoprotein lipase; MOA, mechanism of action; PCSK9, proprotein convertase subtilisin/kexin type 9; siRNA, small interfering RNA; TGRL, triglyceride-rich lipoprotein; Treg, regulatory T cell; VLDL, very-low-density lipoprotein[/B] [ATTACH type="full"]12324[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
New Approaches for the Prevention and Treatment of CVD
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top